Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals Inc (NQ: PHAT )

18.94 +0.67 (+3.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Phathom Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
From Phathom Pharmaceuticals
Via GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Analyst Expectations for Phathom Pharmaceuticals's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023
Via Benzinga
Where Phathom Pharmaceuticals Stands With Analysts
Via Benzinga
Where Phathom Pharmaceuticals Stands With Analysts
Via Benzinga
Phathom Pharmaceuticals Reports First Quarter 2023 Results
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) Near the Top of Equities by Percentage Gain on 4/13
Via Investor Brand Network
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Insiders Buying Phathom Pharmaceuticals And 2 Other Stocks
Although US stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
From Phathom Pharmaceuticals
Via GlobeNewswire
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 469 companies hit new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
Via Benzinga
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
From The Rosen Law Firm, P.A.
Via Business Wire
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 02/17/2023 -- An investigation on behalf of investors in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) was announced over potential breaches of fiduciary duties by... 
Via SBWire
$14M Bet On This Technology Stock? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
From The Rosen Law Firm PA
Via GlobeNewswire
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development... 
Via Benzinga
One Analyst Is Bullish While Another Sees Overhang On Phathom Pharma Stock After Two Rejection Letters
FDA issued two Complete Response Letters to Phathom Pharmaceuticals Inc's (NASDAQ: PHAT) vonoprazan marketing application for the erosive esophagitis (EE) indication and H. pylori (HP) indication... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.